Page last updated: 2024-12-09

2-(2-imidazo[1,2-a]pyridinylmethylthio)-6-nitro-1H-benzimidazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

You're describing a compound with the chemical name **2-(2-imidazo[1,2-a]pyridinylmethylthio)-6-nitro-1H-benzimidazole**. This compound is likely an **imidazo[1,2-a]pyridine derivative**, a class of molecules with diverse biological activity.

Let's break down its structure and potential importance:

* **Imidazo[1,2-a]pyridine:** This is a bicyclic heterocycle, meaning it contains two fused rings with atoms other than carbon (nitrogen in this case).
* **2-(2-imidazo[1,2-a]pyridinylmethylthio):** This part of the name describes a substituent attached to the benzimidazole ring. It indicates a 2-imidazo[1,2-a]pyridinylmethyl group connected through a sulfur atom (thio).
* **6-nitro-1H-benzimidazole:** This describes the core structure of the compound. It's a benzimidazole ring with a nitro group (NO2) at position 6.

**Importance for Research:**

Imidazo[1,2-a]pyridine derivatives have been extensively researched for their potential applications in medicine, particularly as:

* **Anti-cancer agents:** Some derivatives have shown promising activity against various types of cancer, including leukemia, lung cancer, and breast cancer.
* **Anti-inflammatory agents:** This class of compounds can inhibit inflammatory pathways, making them potentially useful for treating inflammatory diseases like rheumatoid arthritis.
* **Antimicrobial agents:** Certain imidazo[1,2-a]pyridine derivatives exhibit activity against bacteria, fungi, and viruses.
* **Neuroprotective agents:** Some derivatives have shown promise in protecting nerve cells from damage, potentially offering therapeutic benefits for neurological disorders.

**Important Considerations:**

It's crucial to note that the specific compound you mentioned (2-(2-imidazo[1,2-a]pyridinylmethylthio)-6-nitro-1H-benzimidazole) might not have been specifically studied for its biological activity.

To determine its potential importance, you would need to:

1. **Identify the source:** Where did you encounter this compound? Is it mentioned in a research article or patent?
2. **Check for published data:** Search scientific databases (PubMed, Google Scholar, etc.) to see if there's any research on its biological activity.
3. **Analyze its structure:** Examine its structural features and compare them to known imidazo[1,2-a]pyridine derivatives with known biological effects. This can provide clues about its potential activity.

In summary, 2-(2-imidazo[1,2-a]pyridinylmethylthio)-6-nitro-1H-benzimidazole is a potential candidate for further research due to the known diverse biological activities of imidazo[1,2-a]pyridine derivatives. However, its exact potential and importance remain to be investigated.

Cross-References

ID SourceID
PubMed CID916344
CHEMBL ID1451126
CHEBI ID105775

Synonyms (20)

Synonym
EU-0073050
smr000212094
MLS000588280
2-(imidazo[1,2-a]pyridin-2-ylmethylsulfanyl)-5-nitro-1h-benzoimidazole
OPREA1_342671
STK361603
2-[(imidazo[1,2-a]pyridin-2-ylmethyl)sulfanyl]-5-nitro-1h-benzimidazole
CHEBI:105775
AKOS002285125
2-(imidazo[1,2-a]pyridin-2-ylmethylsulfanyl)-6-nitro-1h-benzimidazole
HMS2542I20
F1001-0013
328016-66-6
2-((imidazo[1,2-a]pyridin-2-ylmethyl)thio)-5-nitro-1h-benzo[d]imidazole
CHEMBL1451126
Q27183552
2-(2-imidazo[1,2-a]pyridinylmethylthio)-6-nitro-1h-benzimidazole
sr-01000446815
SR-01000446815-1
2-[({imidazo[1,2-a]pyridin-2-yl}methyl)sulfanyl]-5-nitro-1h-1,3-benzodiazole
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
imidazopyridine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency28.18380.01846.806014.1254AID624417
ATAD5 protein, partialHomo sapiens (human)Potency18.35640.004110.890331.5287AID504466
Microtubule-associated protein tauHomo sapiens (human)Potency3.54810.180013.557439.8107AID1460
regulator of G-protein signaling 4Homo sapiens (human)Potency50.11870.531815.435837.6858AID504845
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency10.00000.035520.977089.1251AID504332
DNA polymerase eta isoform 1Homo sapiens (human)Potency19.95260.100028.9256213.3130AID588591
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency35.48130.00798.23321,122.0200AID2551
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]